Wall Street is neutral on Kaleido Biosciences Inc (KLDO). On average, analysts give Kaleido Biosciences Inc a Buy rating. The average price target is $7.675, which means analysts expect the stock to rise by 5016.67% over the next twelve months. That average ranking earns Kaleido Biosciences Inc an Analyst Rating of 11, which is better than 11% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating KLDO a Buy today. Find out what this means to you and get the rest of the rankings on KLDO!